MiMedx集團 MDXG 深 滬
等待開盤 12-24 09:30:00 美东时间
6.99
-0.050
-0.71%
華盛通- 最 高7.04
- 今 開7.00
- 成交量 31.87万股
- 最 低 6.91
- 昨 收 7.04
- 總市值 10.35亿
- 52周最高 9.71
- 市盈率 靜 24.56
- 換手率 0.22%
- 52周最低 5.79
- 委 比 -46.50%
- 總股本 1.48亿
- 歷史最高 18.25
- 量 比 0.38
- 振 幅 1.85%
- 歷史最低 0.83
- 每 手 1
- 風險率 0.83%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多MIMEDX Enters into Exclusive U.S. Distribution Agreement for RegenKit®-Wound Gel
MiMedx Group announced an exclusive agreement with Regen Lab USA LLC to distribute RegenKit®-Wound Gel in the U.S. This autologous PRP and ATS wound gel is FDA-approved, CMS-covered, and effective for treating chronic wounds, particularly diabetic ones. The product enhances MiMedx's Advanced Wound Care portfolio and aligns with their mission to provide innovative healing solutions. The company expects the addition to strengthen its competitive po...
12-22 14:43
美股大行评级 | 德银首予Coinbase"买入"评级，目标价340美元；AERO获多家机构首予超配评级；大摩维持苹果"超配"评级，目标价升至315美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从9美元升至10美元；摩根大通：上调Recursion Pharmaceuticals评级至"超配"，目标价从10美元升至11美元
12-18 10:54
NexGelRx Receives Additional Investment from Eric Gruntfest of Diesis Holdings, LLC and Appoints Him as Board Observer and Strategic Advisor
NEXGEL, Inc. announced that its subsidiary, NexGelRx, has received strategic investments from Eric Gruntfest and Ariel Imas of Diesis Holdings, LLC. Gruntfest, a seasoned healthcare executive, will serve as a board observer and advisor to NexGelRx, bringing expertise in reimbursement strategy, patient access, and healthcare commercialization. NexGelRx aims to leverage its ultra-gentle hydrogel technology for innovative drug delivery solutions. NE...
12-16 13:00
MIMEDX Group Releases Interim Results From Its Campaign Trial, Showing That Its EPIEFFECT Significantly Outperformed Standard Care In Treating Nonhealing Diabetic Foot Ulcers
MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced the publication of interim results from its CAMPAIGN trial, a randomized controlled trial ("RCT") designed to evaluate the performance of the
11-13 21:11
MIMEDX Provides Update on EPIEFFECT® Randomized Controlled Trial
MiMedx announced interim results from its CAMPAIGN trial, showing EPIEFFECT's superiority over standard wound treatment in managing diabetic foot ulcers. Published in *International Journal of Tissue Repair*, the study, based on 71 patients, demonstrated a 98.5% posterior probability of EPIEFFECT's effectiveness. The Company also presented at TRES with an 88-patient sample, further supporting EPIEFFECT's performance. MIMEDX aims to leverage these...
11-13 13:00
MIMEDX to Participate in Upcoming Investor Conferences
MiMedx Group announced that its senior management will attend the Craig-Hallum 16th Annual Alpha Select Conference on November 18, 2025, and the Canaccord MedTech, Diagnostics, and Digital Health & Services Forum on November 20, 2025, both in New York. Investors can arrange meetings by contacting their respective Craig-Hallum or Canaccord representatives. MiMedx is a leader in providing wound care solutions, aiming to be the global leader in heal...
11-10 21:01
MIMEDX Comments on CY 2026 Medicare Physician Fee Schedule Final Rule
MiMedx Group, Inc. ("MIMEDX") has responded to CMS's release of the CY 2026 Physician Fee Schedule final rule, which aims to address fraud, waste, and abuse in the Medicare reimbursement system for skin substitutes. Joseph H. Capper, MIMEDX Chief Executive Officer, stated that while the final rule aligns with earlier proposed changes, it provides a significant opportunity for MIMEDX to leverage its competitive advantages. The company believes the...
11-03 14:15
MiMedx Group shares are trading higher after the company reported Q3 results above estimates.
MiMedx Group shares are trading higher after the company reported Q3 results ab...
10-30 19:42
Earnings Scheduled For October 29, 2025
Companies Reporting Before The Bell • OppFi (NYSE:OPFI) is expected to report q...
10-29 19:11
MIMEDX Announces Launch of EPIXPRESS®
MiMedx Group announced the launch of EPIXPRESS, a new advanced wound care solution. This lyophilized placental allograft features a fenestrated design to enhance fluid movement, improving treatment for hard-to-heal wounds such as diabetic foot ulcers and venous leg ulcers. As part of the company’s AWC portfolio, EPIXPRESS continues MIMEDX’s commitment to innovative, market-driven solutions for wound management.
10-06 13:28
